The Lancet Respiratory Medicine (JCR Q1, IF: 38.7), the leading journal in the fields of respiratory and critical care medicine, published a phase 2 clinical study article on China's first DPP-1 ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...